Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 17/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5187097 | 0.84 | KEAP1 (0.49) | BTK | |
| SCHEMBL6444544 | 0.82 | P2RX7 (0.40) | BTK | |
| SCHEMBL9965010 | 0.80 | BTK (0.65) | BTKPDPK1 | |
| SCHEMBL16333767 | 0.80 | BTK (0.56) | BTKPDPK1IKBKBCHUK | |
| SCHEMBL2424952 | 0.80 | BTK (0.56) | BTKPDPK1IKBKBCHUK | |
| SCHEMBL30954333 | 0.80 | BTK (0.56) | BTKPDPK1 | |
| SCHEMBL16337098 | 0.80 | BTK (0.64) | BTK | |
| SCHEMBL18985011 | 0.80 | BTK (0.60) | BTK | |
| SCHEMBL12215166 | 0.79 | BTK (0.38) | BTKPDPK1BRD4 | |
| SCHEMBL18985042 | 0.79 | BTK (0.62) | BTKBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110891935-B | Bicyclic compounds and their use in cancer treatment | 泰普斯特医疗公司 | 2023-12-01 | — | — | CN | disclosed |
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210024491-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | BTK 2596/4885PDPK1 3854/4885BRD4 11/4885 |
| US-20210024491-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | BTK 2596/4885PDPK1 3854/4885BRD4 11/4885 |
| US-20190315712-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | BTK 2596/4885PDPK1 3854/4885BRD4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.